Cholinesterase inhibitors: Tremor and exacerbation of Parkinson's disease

Prescrire International

Volumn 16, Issue 91, 2007, Pages 197-198

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBIDOPA; CHOLINESTERASE INHIBITOR; DILTIAZEM; DONEPEZIL; GALANTAMINE; LEVODOPA; NEUROLEPTIC AGENT; PLACEBO; RIVASTIGMINE; TRIMETAZIDINE; VERAPAMIL;

AKATHISIA; ALZHEIMER DISEASE; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; FALLING; FRANCE; GAIT; GAIT DISORDER; GASTROINTESTINAL TOXICITY; HUMAN; LEWY BODY; MENTAL DISEASE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT DURATION; TREMOR;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DEMENTIA; DYSTONIA; FRANCE; GALANTAMINE; HUMANS; INDANS; LEWY BODY DISEASE; PARKINSON DISEASE; PHENYLCARBAMATES; PIPERIDINES; TREMOR;

EID: 34948859075     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Prescrire Editorial Staff "Donepezil" Prescrire Int 1998; 7(37): 146-147.
2. Prescrire Editorial Staff "Rivastigmine" Prescrire Int 1999; 8 (40): 47-48.
3. Prescrire Editorial Staff "Galantamine" Prescrire Int 2001; 10 (56): 180-181.
4. Prescrire Editorial Staff "Anticholinesterases in Alzheimer's disease" Prescrire Int 2003; 12 (68): 230-231.
5. "Donepezil hydrochloride". In: "Martindale The Complete Drug Reference" The Pharmaceutical Press, London. Website http://www.medicinescomplete.com/mc/martindale accessed 22 September 2006: 5 pages.
6. "Chlorpromazine". In:"Martindale The Complete Drug Reference" The Pharmaceutical Press, London. Website http://www.medicinescomplete.com/mc/martindale accessed 22 September 2006: 39 pages.
7. Thomson, Montvale 2005: 1197-1200.
8. o". In: "Physicians' Desk Reference" Thomson, Montvale 2005: 2304-2307.
9. o". In: "Physicians' Desk Reference" Thomson, Montvale 2005: 1736-1741.
10. Raskind MA et at. "Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension" Neurology 2000; 54: 2261-2268.
11. Canadian Adverse Drug Reaction Monitoring Program "Donepezil: suspected adverse reactions" Can Med Assoc J 1998; 159 (1): 81.
12. Vanacore N et al. "Pisa syndrome in a cohort of Alzheimer's disease patients" Acta Neurol Scand 2005; 111: 199-201.
13. Miyaoka T et al. "Pisa syndrome due to a cliolinesterase inhibitor (donepezil): a case report" J Clin Psychiatry 2001; 62: 573-574.
14. Kwak YT et al. "Relation between cholinesterase inhibitor and Pisa syndrome" Lancet 2000; 355 (9222): 2222.
15. Villarejo A et al. "Cholinergic-dopaminergic imbalance in Pisa syndrome" Clin Neuropharmacol 2003; 26 (3): 119-121.
16. Prescrire Rédaction "12-4. Patients parkinsoniens" Rev Prescrire 2006; 26 (270, suppl. interactions médicamenteuses): 102-109.
17. Prescrire Rédaction "Syndrome parkinsonien et inhibiteurs calciques" Rev Prescrire 2002; 22 (234): 828-829.
18. Emre M et al, "Rivastigmine for dementia associated with Parkinson's disease" N Engl J Med 2004; 351 (24): 2509-2518.
19. Leroi I et al. "Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease" Int J Geriatr Psychiatry 2004, 19: 1-8.
20. Maidment ID et al. "A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia" Acta Psychiatr Scand 2005; 111: 403-409.
21. Brashear A et al. "Double-blind placebo-controlled trial of donepezil in patients with Parkinson's disease and related dementia" Movement Disorder Highlights from the 56th AAN meeting 2005: 1 page.
22. Giladi N et al. "Rivastigmine (Exelon) for dementia in patients with Parkinson's disease" Acta Neurol Scand 2003; 108 (5): 368-373.
23. Ravina B et al. "Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo-controlled, crossover study" J Neurol Neurosurg Psychiatry 2005; 76 (7): 934-939.
24. The European Agency for the Evaluation of Medicinal Products - Committee for Medicinal Products for Human Use "Post-Authorisation Summary of Opinion for Exelon" 13 October 2005: 1 page.
25. The European Agency for the Evaluation of Medicinal Products - Committee for Medicinal Products for Human Use "Post-Authorisation Summary of positive opinion for Exelon" 26 January 2006: 1 page.
26. "Dementia". In: "Martindale The complete drug reference" The Pharmaceutical Press, London. Website http://www.medicinescomplete.com/mc/martindale accessed 22 September 2006: 5 pages.
27. Sanders J et al. "Donepezil in dementia with Lewy bodies: treatment and withdrawal" Int Psychogeriatr 2001; 13 (suppl. 2): P-123.
28. Shea C et al. "Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients" Int Psychogeriatr 1998, 10 (3): 229-238.